AWAaron T. Wild

Aaron T. Wild

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aaron T. Wild has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 28 July 2015
      • Vol. 2  (2) , 56-60, 62, 64

    IMPROVING SAFE PATIENT THROUGHPUT IN A MULTIDISCIPLINARY ONCOLOGY CLINIC.

    by Shereef M Elnahal, Shereef M Elnhal, Shalini Moningi, Aaron T Wild, Avani S Dholakia, Mary Hodgin, Katherine Y Fan, Peng Huang, Peter Pronovost, Timothy M Pawlik, et al.


  • Open Access

    Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships

    by Avani S. Dholakia, Amy Hacker-Prietz, Aaron T. Wild, Siva P. Raman, Laura D. Wood, Peng Huang, Daniel A. Laheru, Lei Zheng, Ana De Jesus-Acosta, Dung T. Le, et al.

    Objective Neoadjuvant therapy increases rates of margin-negative resection of borderline resectable pancreatic ductal adenocarcinoma (BL-PDAC). Criteria for BL-PDAC resection following neoadjuvant chemotherapy and radiation therapy (NCRT) have not been clearly defined. Methods Fifty consecutive patients with BL-PDAC who received NCRT from 2007 to 2012 were identified. Computed tomography (CT) scans pre- and post-treatment were centrally reviewed. Results Twenty-nine patients (58 %) underwent resection following NCRT, while 21 (42 %) remained unresected. Patients selected for and successfully undergoing resection were more likely to have better performance status and absence of the following features on pre- and post-treatment CT: superior mesenteric vein/portal vein encasement, superior mesenteric artery involvement, tumor involvement of two or more vessels, and questionable/overt metastases (all p < 0.05). Tumor volume and degree of tumor–vessel involvement did not significantly change in both groups after NCRT (all p > 0.05). The median overall survival was 22.9 months in resected versus 13.0 months in unresected patients (p < 0.001). Of patients undergoing resection, 93 % were margin-negative, 72 % were node-negative, and 54 % demonstrated moderate pathologic response to NCRT. Conclusion Apparent radiographic extent of vascular involvement does not change significantly after NCRT. Patients without metastatic disease should be chosen for surgical exploration based on adequate performance status and lack of disease progression.


  • Management of pancreatic cancer

    by Aaron T. Wild, Katherine Y. Fan, Joseph M. Herman


  • Open Access

    Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

    by Sara Alcorn, Amanda J. Walker, Nishant Gandhi, Amol Narang, Aaron T. Wild, Russell K. Hales, Joseph M. Herman, Danny Y. Song, Theodore L. DeWeese, Emmanuel S. Antonarakis, et al.

    As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.


  • Open Access

    Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells

    by Nishant Gandhi, Aaron T. Wild, Sivarajan T. Chettiar, Khaled Aziz, Yoshinori Kato, Rajendra P. Gajula, Russell D. Williams, Jessica A. Cades, Anvesh Annadanam, Danny Song, et al.

    Outcomes for poor-risk localized prostate cancers treated with radiation are still insufficient. Targeting the “non-oncogene” addiction or stress response machinery is an appealing strategy for cancer therapeutics. Heat-shock-protein-90 (Hsp90), an integral member of this machinery, is a molecular chaperone required for energy-driven stabilization and selective degradation of misfolded “client” proteins, that is commonly overexpressed in tumor cells. Hsp90 client proteins include critical components of pathways implicated in prostate cancer cell survival and radioresistance, such as androgen receptor signaling and the PI3K-Akt-mTOR pathway. We examined the effects of a novel non-geldanamycin Hsp90 inhibitor, AUY922, combined with radiation (RT) on two prostate cancer cell lines, Myc-CaP and PC3, using in vitro assays for clonogenic survival, apoptosis, cell cycle distribution, γ-H2AX foci kinetics and client protein expression in pathways important for prostate cancer survival and radioresistance. We then evaluated tumor growth delay and effects of the combined treatment (RT-AUY922) on the PI3K-Akt-mTOR and AR pathways in a hind-flank tumor graft model. We observed that AUY922 caused supra-additive radiosensitization in both cell lines at low nanomolar doses with enhancement ratios between 1.4–1.7 (p < 0.01). RT-AUY922 increased apoptotic cell death compared with either therapy alone, induced G2-M arrest and produced marked changes in client protein expression. These results were confirmed in vivo, where RT-AUY922 combination therapy produced supra-additive tumor growth delay compared with either therapy by itself in Myc-CaP and PC3 tumor grafts (both p < 0.0001). Our data suggest that combined RT-AUY922 therapy exhibits promising activity against prostate cancer cells, which should be investigated in clinical studies.


  • Sa1522 Comparative Analysis of Traditional and Visicoil Fiducials Implanted During Endoscopic Ultrasound for Pancreatic Cancer Patients Receiving Stereotactic Body Radiation Therapy

    by Katherine Kim, Erik J. Tryggestad, Aaron T. Wild, Mark A. Ziegler, Eun J. Shin, Reem Z. Sharaiha, Vikesh K. Singh, Anne Marie Lennon, Marcia I. Canto, Joseph M. Herman, et al.